Update on the Treatment of Pituitary Diseases: Emerging Therapies
Date & Location
Friday, April 12, 2019, 8:30 AM - 4:30 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY
Endocrinology, Diabetes & Metabolism, ENT, Head and Neck Oncology, Industry, Internal Medicine , Molecular Pathology, Neuro-Oncology, Neurology, Neuroradiology, Neurosurgery, Nuclear Medicine, Nurse Practitioner, Nursing, Pathology, Physician Assistant, Radiation Oncology, Radiology-Diagnostic, Radiology-Interventional, Research Fellow, Surgical Oncology, Surgical Pathology
This course aims to improve patient care and outcomes through evidence-based discussion of clinical practice guidelines and emerging therapies in order to assess and update current practices to promote earlier diagnosis and treatment of pituitary diseases. The multidisciplinary nature of the course will allow for dissemination of knowledge across the variety of practitioners caring for pituitary patients, and for the patients themselves.
After completion of this didactic and case-based educational activity, participants will be up to date on the latest developments in ongoing basic and translational science as well as the clinical management of patients with pituitary conditions. Participants will be able to review available and emerging medical therapies for Cushing’s and acromegaly, discuss new therapies for aggressive and malignant tumors, understand decision making involved in surgical intervention for pituitary tumors, get an overview on potential surgical complications, describe the role of radiation therapy for pituitary tumors, review neuro-ophthalmological findings in pituitary disease risks, discuss treatment of immunotherapy-related pituitary dysfunction, and assess advances in neuroimaging and tumor markers that may predict tumor behavior and clinical outcomes.
This course is intended for endocrinologists, neurosurgeons, otolaryngologists, radiation oncologists, neurologists, ophthalmologists, neuro-oncologists, family medicine and internal medicine physicians, physicians in training and other allied health professionals who treat and manage patients with pituitary diseases. We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions.
Request for Case Submissions
There will be a tumor board during the provider/clinical breakout session from 1:30-3:00 pm where attendees and faculty will review cases. Attendees will have an opportunity to submit a case for discussion during the course at registration. In order to prepare your submission, we ask that you provide a BRIEF summary of your case and include key lab results. Please ensure that all identifiable PHI has been removed. Cases should have an educational purpose. The course faculty will not be able to provide a detailed/complex consult review during the course and they will try to get through as many cases as possible.
Patient Breakout Session
We also invite patients with pituitary disease and their caregivers to attend this educational activity and participate in our interactive afternoon breakout sessions. Pituitary patients will be able to review treatment options, learn about ongoing clinical trials, and discuss their comprehensive care with providers and other patients. The educational objective of this patient session is to provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients. Please note AMA PRA Category 1 Credits™ will not be offered for the Patient Breakout Session. MSK is pleased to invite patients and caregivers to attend this course on a complimentary basis. If you are a patient or caregiver interested in attending, please email [email protected] to register (please note that registration is required in order to attend).
Live Simulcast Available
We are pleased to offer the Update on the Treatment of Pituitary Diseases: Emerging Therapies Course via live simulcast. Attendees registered for the live simulcast option will receive detailed instructions via email prior to the start of the course. This will include information on how to engage with the faculty (through an online Q&A) as well as information on how to claim CME credit - active participation throughout the live simulcast is encouraged. Register for the live simulcast.
The live simulcast option is available for MSK employees who work outside of the New York City area only, including Bergen, Westchester, Basking Ridge, Monmouth, Rockville Centre, Commack and Hauppauge. MSK employees within the New York city area are welcome to attend this course in person at Zuckerman Research Center.
Please note that the simulcast will only be offered for the Provider/Clinical Track of this program.
- Review the efficacy and side effect profiles of treatment options, including emerging therapies, for Cushing’s and acromegaly
- Discuss surgical outcomes and risk management for pituitary and skull base tumors
- Describe recent advances in pituitary neuropathology and neuroimaging
- Critically appraise the role of radiation therapy in the management of pituitary tumors
- Debate treatment decisions supporting the use and timing of new therapies for aggressive and malignant pituitary tumors
- Provide a forum for pituitary patients to discuss treatment options and new therapies with providers and other patients